The short version of peptide fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
=== EC 1.13.11 With incorporation of two atoms of oxygen === EC 1.13.11.1: catechol 1,2-dioxygenase EC 1.13.11.2: catechol 2,3-dioxygenase EC 1.13.11.3: protocatechuate 3,4-dioxygenase EC 1.13.11.4: gentisate 1,2-dioxygenase EC 1.13.11.5: homogentisate 1,2-dioxygenase EC 1.13.11.6: 3-hydroxyanthranilate 3,4-dioxygenase EC 1.13.11.7: deleted EC 1.13.11.8: protocatechuate 4,5-dioxygenase EC 1.13.11.9: 2,5-dihydroxypyridine 5,6-dioxygenase EC 1.13.11.10: 7,8-dihydroxykynurenate 8,8a-dioxygenase EC 1.13.11.11: tryptophan 2,3-dioxygenase EC 1.13.11.12: linoleate 13S-lipoxygenas EC 1.13.11.13: The activity is the sum of several enzymatic and spontaneous reactions EC 1.13.11.14: 2,3-dihydroxybenzoate 3,4-dioxygenase EC 1.13.11.15: 3,4-dihydroxyphenylacetate 2,3-dioxygenase EC 1.13.11.16: 3-carboxyethylcatechol 2,3-dioxygenase EC 1.13.11.17: indole 2,3-dioxygenase EC 1.13.11.18: persulfide dioxygenase EC 1.13.11.19: cysteamine dioxygenase EC 1.13.11.20: cysteine dioxygenase EC 1.13.11.21: Now EC 1.14.99.36, β-carotene 15,15′-monooxygenase EC 1.13.11.22: caffeate 3,4-dioxygenase EC 1.13.11.23: 2,3-dihydroxyindole 2,3-dioxygenase EC 1.13.11.24: quercetin 2,3-dioxygenase EC 1.13.11.25: 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 4,5-dioxygenase EC 1.13.11.26: peptide-tryptophan 2,3-dioxygenase EC 1.13.11.27: 4-hydroxyphenylpyruvate dioxygenase EC 1.13.11.28: 2,3-dihydroxybenzoate 2,3-dioxygenase EC 1.13.11.29: stizolobate synthase EC 1.13.11.30: stizolobinate synthase EC 1.13.11.31: arachidonate 12-lipoxygenase EC 1.13.11.32: Now EC 1.13.12.16, nitronate monooxygenase EC 1.13.11.33: arachidonate 15-lipoxygenase EC 1.13.11.34: arachidonate 5-lipoxygenase EC 1.13.11.35: pyrogallol 1,2-oxygenase EC 1.13.11.36: chloridazon-catechol dioxygenase EC 1.13.11.37: hydroxyquinol 1,2-dioxygenase EC 1.13.11.38: 1-hydroxy-2-naphthoate 1,2-dioxygenase EC 1.13.11.39: biphenyl-2,3-diol 1,2-dioxygenase EC 1.13.11.40: arachidonate 8-lipoxygenase EC 1.13.11.41: 2,4′-dihydroxyacetophenone dioxygenase EC 1.13.11.42: identical to EC 1.13.11.11, tryptophan 2,3-dioxygenase EC 1.13.11.43: lignostilbene αβ-dioxygenase EC 1.13.11.44: Activity is covered by EC 1.13.11.60, linoleate 8R-lipoxygenase and EC 5.4.4.6, 9,12-octadecadienoate 8-hydroperoxide 8S-isomerase EC 1.13.11.45: linoleate 11-lipoxygenase EC 1.13.11.46: 4-hydroxymandelate synthase EC 1.13.11.47: 3-hydroxy-4-oxoquinoline 2,4-dioxygenase EC 1.13.11.48: 3-hydroxy-2-methyl-quinolin-4-one 2,4-dioxygenase EC 1.13.11.49: chlorite O2-lyase EC 1.13.11.50: acetylacetone-cleaving enzyme EC 1.13.11.51: 9-cis-epoxycarotenoid dioxygenase EC 1.13.11.52: indoleamine 2,3-dioxygenase EC 1.13.11.53: acireductone dioxygenase (Ni2+-requiring) EC 1.13.11.54: acireductone dioxygenase [iron(II)-requiring] EC 1.13.11.55: sulfur oxygenase/reductase EC 1.13.11.56: 1,2-dihydroxynaphthalene dioxygenase EC 1.13.11.57: gallate dioxygenase EC 1.13.11.58: linoleate 9S-lipoxygenase EC 1.13.11.59: torulene dioxygenase EC 1.13.11.60: inoleate 8R-lipoxygenase EC 1.13.11.61: linolenate 9R-lipoxygenase EC 1.13.11.62: linoleate 10R-lipoxygenase EC 1.13.11.63: β-carotene 15,15′-dioxygenase EC 1.13.11.64: 5-nitrosalicylate dioxygenase EC 1.13.11.65: carotenoid isomerooxygenase EC 1.13.11.66: hydroquinone 1,2-dioxygenase EC 1.13.11.67: 8′-apo-β-carotenoid 14′,13′-cleaving dioxygenase EC 1.13.11.68: 9-cis-β-carotene 9′,10′-cleaving dioxygenase EC 1.13.11.69: carlactone synthase EC 1.13.11.70: all-trans-10′-apo-β-carotenal 13,14-cleaving dioxygenase EC 1.13.11.71: carotenoid-9′,10′-cleaving dioxygenase EC 1.13.11.72: 2-hydroxyethylphosphonate dioxygenase EC 1.13.11.73: methylphosphonate synthase EC 1.13.11.74: 2-aminophenol 1,6-dioxygenase EC 1.13.11.75: all-trans-8′-apo-β-carotenal 15,15′-oxygenase EC 1.13.11.76: 2-amino-5-chlorophenol 1,6-dioxygenase EC 1.13.11.77: oleate 10S-lipoxygenase EC 1.13.11.78: 2-amino-1-hydroxyethylphosphonate dioxygenase (glycine-forming) EC 1.13.11.79: aerobic 5,6-dimethylbenzimidazole synthase EC 1.13.11.80: (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase EC 1.13.11.81: 7,8-dihydroneopterin oxygenase EC 1.13.11.82: 8′-apo-carotenoid 13,14-cleaving dioxygenase EC 1.13.11.83: 4-hydroxy-3-prenylphenylpyruvate oxygenase EC 1.13.11.84: crocetin dialdehyde synthase EC 1.13.11.85: exo-cleaving rubber dioxygenase EC 1.13.11.86: 5-aminosalicylate 1,2-dioxygenase EC 1.13.11.87: endo-cleaving rubber dioxygenase EC 1.13.11.88: isoeugenol monooxygenase EC 1.13.11.89: (hydroxymethyl)phosphonate dioxygenase EC 1.13.11.90: [1-hydroxy-2-(trimethylamino)ethyl]phosphonate dioxygenase (glycine-betaine-forming) EC 1.13.11.91: 3-mercaptopropionate dioxygenase EC 1.13.11.92: fatty acid α-dioxygenase
== Chondrocyte Primary Culture == Chondrocytes can be prepared by sequential enzymatic digestion of cartilage with Pronase and Collagenase and cultured in DMEM-F12 cell culture media. Transplantation of dedifferentiated chondrocytes often leads to the formation of fibrous tissue formation. Redifferentiation of dedifferentiated chondrocytes in the 3-D system (spheroid culture) restore morphological and functional properties.
A story with Frazier Tharpe for GQ, published on June 2, 2025, started by stating that Clipse were unimpressed with the current state of mainstream hip-hop. The brothers gave Stove God Cooks and Future as exceptions. Pusha T lamented the feelings of loneliness and need to play "industry games" that came with his solo career, revealed that he was already becoming disillusioned with his former boss West during the 2019 recording sessions for Jesus Is King, and criticized West for his perceived character flaws. He also denied being a bad friend to West. The story of Clipse's dispute with Def Jam Recordings was told for the first time in this interview. Also included were comments about Drake suing Universal Music Group ("The suing thing is bigger than some rap shit. I just don't rate you.") and more details about the album: tracks "Mike Tyson", "POV", "F.I.C.O.", and features from Stove God Cooks and Lamar. After the release of "So Be It", GQ published a follow-up article (with unused excerpts from the interview) in which the song was discussed, including lyrics from Pusha T which diss Travis Scott. Another interview with Andre Gee for Rolling Stone was published on June 9. Clipse elaborated on their distribution deal with Roc Nation and announced a nationwide United States tour, planned to take place across twenty-five shows from August 3 to September 10.
Sources: en.wikipedia.org
=== Introduction of consumer-ready hardware (2010s–present) === The popularity of digital gaming across multiple forms like mobile, console, or PC gaming, led technology giants to further invest in the development of VR technology. In a thriving gaming market, the advancement in VR technology has been a point of great interest in the age of modern gaming. One catalyst to this modern VR boom was the obsession and great success of Pokémon Go in 2016, which incorporated basic VR concepts, stirring the world with technological breakthroughs in gaming such as VR effects, combining real life scenes with the virtual world, as well as the concept of enjoying gaming alongside interaction in the real world. After decades of attempts from its introduction, low-cost, consumer-grade VR hardware began to appear in the 2010s. The Oculus Rift is considered the first consumer-ready VR headset and was first released in 2016. The unit was developed by Palmer Luckey, and first announced in 2013 as an inexpensive VR option for video games. During testing, Luckey had gained the help of id Software's John Carmack to develop a VR version of Doom 3 for Oculus. While this helped to successfully demonstrate the Oculus, which led to Facebook acquiring Oculus in 2014 for $2 billion, it also led to a lawsuit between ZeniMax Media, id's parent company, against Oculus over intellectual property theft over Carmack's participation. The case was settled out of court. Nine games were available at launch and Oculus had established a number of partnerships to provide more games following its release.
== Alternative Medicine == The effect of Ayurvedic treatments has been researched, however due to methodological flaws of relevant studies and research, it has not been possible to draw conclusions regarding efficacy of these treatments and there is insufficient evidence to recommend them.
=== Bivalves === Argopecten purpuratus, peruvian scallop (2018) Bathymodiolus platifrons, seep mussel (2017) Chlamys farreri, Zhikong scallop (2017) Crassostrea angulata, Portuguese oyster (2023) Crassostrea gigas, Pacific oyster (2012) Dreissena rostriformis, Quagga mussel (2019) Limnoperna fortunei, invasive golden mussel (2017) Margaritifera margaritifera, European freshwater pearl mussel (2023) Modiolus philippinarum, shallow water mussel (2017) Mytilus galloprovincialis, Mediterranean mussel (2016) Panopea generosa, Pacific geoduck (2023) Patinopecten yessoensis, Yesso scallop (2017) Pecten maximus, Great scallop (2020) Pinctada fucata, Pearl oyster (2012) Ruditapes philippinarum, Manila clam (2017) Saccostrea glomerata, Sydney rock oyster (2018) Scapharca broughtonii, Blood clam (2019) Tridacna crocea, Giant clam (2023) Venustaconcha ellipsiformis, freshwater mussel (2018)
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.